C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway

Guo, Jing; Tong, Chang-Yong; Shi, Jianguang; Li, Xinjian

doi:10.1080/21655979.2022.2048984

Cited by 13 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Yura M et al [37] found that the increased expression level of CCR7 in ESCC cells consequently increased their invasive ability and malignancy, which may result in a worse prognosis for ESCC patients. Guo J et al [38] revealed that CXCL12/CXCR7 regulates EMT and other malignant processes by activating the STAT3 pathway to accelerate the growth and metastasis of esophageal cancer. A novel prognostic chemokine-related lncRNA model may improve monitoring and management of malignancies including ESCC.…”

Section: Discussionmentioning

confidence: 99%

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer

et al. 2023

View full text Add to dashboard Cite

Background Esophageal squamous cell carcinoma (ESCC) is closely correlated with malignant biological characteristics and poor survival. Recently, chemokines have been reported to be involved in the progression of tumors, and they can also regulate the tumor microenvironment. However, it is unclear whether chemokine-related long noncoding RNAs (lncRNAs) affect the prognosis of ESCC. Methods We downloaded RNA-seq and clinical data from the Gene Expression Omnibus (GEO database. Chemokine-related lncRNAs were screened by differential analysis and Pearson correlation analysis. Then, prognosis-related lncRNAs were screened by using univariate COX regression, and risk models were constructed after the least absolute shrinkage and selection operator (LASSO) regression and multivariate COX regression. The predictive value of the signature was assessed using Kaplan–Meier test, time-dependent receiver operating characteristic (ROC) curves, decision curve analysis (DCA) and calibration curve. Moreover, a nomogram to predict patients’ 1-year 3-year and 5-year prognosis was constructed. Gene set enrichment analyses (GSEA), Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG), evaluation of immune cell infiltration, and estimation of drug sensitivity were also conducted. Results In this study, 677 chemokine-related lncRNAs were first obtained by differential analysis and Pearson correlation. Then, six chemokine-related lncRNAs were obtained by using univariate COX, LASSO and multivariate COX to construct a novel chemokine-related lncRNAs risk model. The signature manifested favorable predictive validity and accuracy both in the testing and training cohorts. The chemokine-related signature could classify ESCC patients into two risk groups well, which indicated that high-risk group exhibited poor prognostic outcome. In addition, this risk model played an important role in predicting signaling pathways, immune cell infiltration, stromal score, and drug sensitivity in ESCC patients. Conclusions These findings elucidated the critical role of novel prognostic chemokine-related lncRNAs in prognosis, immune landscape, and drug therapy, thus throwing light on prognostic evaluation and therapeutic targets for ESCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previous research studies have confirmed that EMT not only participates in the carcinogenesis and progression of malignancies but also plays a unique role in cancer metastasis and chemorefractoriness [3][4][5]. In vitro analysis of an immunodeficient mouse model also indicated EMT was involved in the regulation of tumors, which greatly enhanced tumor cell self-renewal and differentiation [6][7][8].…”

Section: Introductionmentioning

confidence: 89%

TRIM9 Interacts with ZEB1 to Suppress Esophageal Cancer by Promoting ZEB1 Protein Degradation via the UPP Pathway

Lin

Huang

Zhu

et al. 2023

BioMed Research International

View full text Add to dashboard Cite

Background. Esophageal cancer remains one of the most lethal malignant diseases globally. Previous studies indicated that TRIM9 (Tripartite Motif Containing 9) is a potential marker in breast cancer patients. Therefore, in the current research, we intended to clarify the regulatory network of TRIM9 and its relative role in esophageal cancer patients. We aimed to elucidate the regulatory role of TRIM9 in esophageal cancer. Methods. Clinical tumor tissue samples combined with cancer cell line models were utilized to explore the TRIM9 expression pattern. Functional experiments including transwell assay, cell viability assay, and ubiquitination blocking experiments were performed to evaluate the role of the TRIM9/ZEB1 (zinc finger E-box binding homeobox 1) axis and UPP pathway in esophageal cancer progression and exacerbation. Results. Both esophageal cancer samples and cell line models showed significantly suppressed levels of TRIM9. Functional experiments confirmed that TRIM9 overexpression inhibited the cell viability, invasiveness, and stem-like phenotype of cancer cells. Subsequent investigations suggested that TRIM9-ZEB1 interaction accelerated ZEB1 protein degradation through the modulation of the UPP pathway, which confirmed the protective role of TRIM9 in esophageal cancer progression and metastasis. Conclusion. This study concluded that TRIM9 was a tumor suppressor that interacted with ZEB1 and accelerated ZEB1 protein degradation via the ubiquitin-proteasome pathway (UPP). Our research emphasized TRIM9-ZEB1 interaction as a valuable target for esophageal cancer treatment in future development. More detailed studies are needed to further consolidate our findings.

show abstract

“…This problem also increases the probability of lymphatic and hematogenous metastasis. [ 2 ] Radiotherapy and chemotherapy eliminate not only tumor cells but also normal cells, causing harm to patients. Cancer can trigger tumor‐specific immune responses, which has spurred the development of cancer vaccines.…”

Section: Overview Of Cancer Vaccinesmentioning

confidence: 99%

Application of Nanotechnology in Therapeutic Cancer Vaccines

Guo

Tang

et al. 2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Cancer can significantly lower the quality of life of human beings. Numerous treatments have thus far been developed to treat cancer, namely, surgery, radiotherapy, and chemotherapy. [1] Cancer treated with surgery has a high chance of recurrence because the boundary between the malignant tumor and the surrounding tissues and organs is indistinct. This problem also increases the probability of lymphatic and hematogenous metastasis. [2] Radiotherapy and chemotherapy eliminate not only tumor cells but also normal cells, causing harm to patients. Cancer can trigger tumor-specific immune responses, which has spurred the development of cancer vaccines. [3] Cancer vaccines can induce tumor regression or prevent tumor formation while establishing an enduring antitumor memory effect. [4] 1.1. Basic Concepts Cancer vaccines typically include tumor antigens, adjuvants, and delivery vehicles. The effectiveness of cancer vaccines primarily relies on three critical steps (Figure 1): 1) antigen uptake by antigenpresenting cells (APCs); 2) presentation of antigens to T cells by APC, followed by T cell activation; and 3) elimination of tumors by effector T cells. [5] Poor stability of antigens, immune escape, and low immunogenicity hinder the development of cancer vaccines. [6] Adjuvants that can improve the adaptive immune response of the body to antigens have been developed in response to the weak immunogenicity of cancer vaccines. [7] They enhance immune responses to tumor antigens, [8] as well as effectively avoid the immune suppression produced by the body, [9] thereby improving the immunotherapy efficiency of cancer vaccines. Aluminum salt adjuvants, pattern recognition receptor agonists, and polypeptides, among others, exhibit good immune activation. [10] Polymeric nanoparticles provide a promising platform for delivering adjuvants that can enhance antigen uptake by adjusting physical and chemical properties, including shape, size, electrical properties, polarity, processing, and presentation. [11] In addition, nanoadjuvants can enhance the stability of antigens and influence the release kinetics of cancer vaccines. [12] Tumor antigens can be classified as tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). [13] TAAs are more highly expressed in tumor cells than in normal tissues but lack complete specificity for tumors. In contrast, TSAs are abnormal proteins produced by cancer cells via nonsynonymous mutations. [14] TSAs are expressed on tumor cells and are relatively highly immunogenic. [15] The high safety and the reduced off-target side effects render TSAs ideal as targets for tumor immunotherapy. [16] With the rapid development of genomics and bioinformatics, the screening and identification of TSAs are more accurate and faster. Cancer therapeutic vaccines based on TSAs have demonstrated clinical efficacy and exhibited good application prospects. [17] History and Current SituationThe history of tumor antigens and cancer vaccines is summarized in Figure 2. William Coley discovered a mixed bacterial

show abstract

C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway

Cited by 13 publications

References 40 publications

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer

TRIM9 Interacts with ZEB1 to Suppress Esophageal Cancer by Promoting ZEB1 Protein Degradation via the UPP Pathway

Application of Nanotechnology in Therapeutic Cancer Vaccines

Contact Info

Product

Resources

About